alexa Antimalarial and Anti-hypoglycemic

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Antimalarial and Anti-hypoglycemic

Malaria is a major health problem in Tropical and Sub-tropical regions. It contributes significantly to the overall malaria burden in Southeast Asia. An estimated 3.3 billion of the total world population live in areas with malaria risk and an estimated death of 660,000 . This disease is caused by protozoa parasite in genus Plasmodium and transmitted by female Anopheles mosquito. For decades, drug resistance has been one of the main obstacles in the fight against malaria.

It is responsible for the spread of malaria to new areas, the recurrence of malaria in areas where the disease had been eradicated and plays an important role in the occurrence and severity of epidemics in some parts of the world . Furthermore, the difficulty of creating efficient vaccines and also adverse side effects of the existing antimalarial drugs highlight the urgent need for new antimalarial drugs for treatment of malaria. In addition, malaria-associated hypoglycemia has been reported during malaria parasite infection, and is one of all most causes of death.

According to several reports, up to 80% of world’s populations rely on traditional medicine mainly on herbal remedies as primary source of medicinal agents for the treatment of diseases. Some antimalarial drugs in use today (quinine and artemisinin) were either obtained from plants or developed using their chemical structures as templates.

For more information:

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger